---
input_text: 'Oral decitabine cedazuridine with and without venetoclax in higher-risk
  myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched
  study. Hypomethylating agents (HMA) are indicated in the treatment of higher-risk
  myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The
  combination of hypomethylating agents with venetoclax (Ven) has demonstrated promising
  results in these diseases, although randomized clinical trials are needed for validation.
  In this retrospective study, we compared two matched cohorts of patients with MDS
  or CMML: one receiving oral decitabine-cedazuridine (DEC-C, n = 73) and one receiving
  DEC-C and Ven (DEC-C-Ven, n = 51), in three contemporary clinical trials. The aim
  is to determine the impact of the addition of Ven to HMA in MDS and CMML. Individuals
  were matched using a propensity score approach that was based on the IPSS-M score
  and age. All patients had excess blasts; 84% were diagnosed with MDS and 16% with
  CMML. Most patients had high- or very high-risk disease, according to the revised
  IPSS-R. The overall response rate was superior in the DEC-C-Ven cohort (90% vs 64%,
  P = 0.002). The median times to best response were 1.1 and 2.7 months for the DEC-C-Ven
  and DEC-C cohorts, respectively (P < 0.001). More patients underwent hematopoietic
  stem cell transplantation in the DEC-C-Ven cohort (47%) than in the DEC-C cohort
  (16%, P < 0.001). The 4- and 8-week mortality did not significantly differ between
  the DEC-C and DEC-C-Ven cohorts. Patients in the DEC-C-Ven cohort had a more profound
  neutropenia at days 15 and 21 of the first cycle. The median overall survival was
  24 and 19 months for the DEC-C-Ven and DEC-C cohorts, respectively (P = 0.89), and
  the median event-free survival durations were 18 and 10 months (P = 0.026). In conclusion,
  the addition of Ven resulted in improved response rates and outcomes in specific
  subgroups; prospective clinical trials are needed to confirm these findings.'
raw_completion_output: |-
  primary_disease: higher-risk myelodysplastic syndromes; chronic myelomonocytic leukemia

  medical_actions: use of hypomethylating agents; addition of venetoclax to hypomethylating agents; hematopoietic stem cell transplantation

  symptoms: excess blasts; high- or very high-risk disease; neutropenia

  chemicals: decitabine; cedazuridine; venetoclax

  action_annotation_relationships: use of hypomethylating agents TREATS high- or very high-risk disease IN higher-risk myelodysplastic syndromes; use of hypomethylating agents TREATS high- or very high-risk disease IN chronic myelomonocytic leukemia; addition of venetoclax (with decitabine and cedazuridine) TREATS excess blasts IN higher-risk myelodysplastic syndromes; addition of venetoclax (with decitabine and cedazuridine) TREATS excess blasts IN chronic myelomonocytic leukemia; hematopoietic stem cell transplantation TREATS higher-risk myelodysplastic syndromes; hematopoietic stem cell transplantation TREATS chronic myelomonocytic leukemia
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  hematopoietic stem cell transplantation TREATS chronic myelomonocytic leukemia

  ===

extracted_object:
  primary_disease: higher-risk myelodysplastic syndromes; chronic myelomonocytic leukemia
  medical_actions:
    - use of hypomethylating agents
    - addition of venetoclax to hypomethylating agents
    - MAXO:0000747
  symptoms:
    - excess blasts
    - high- or very high-risk disease
    - HP:0001875
  chemicals:
    - CHEBI:50131
    - cedazuridine
    - CHEBI:133021
  action_annotation_relationships:
    - subject: use of hypomethylating agents
      predicate: TREATS
      object: high- or very high-risk disease
      qualifier: higher-risk myelodysplastic syndromes
      subject_extension: hypomethylating agents
    - subject: use of hypomethylating agents
      predicate: TREATS
      object: high- or very high-risk disease
      qualifier: MONDO:0020311
      subject_extension: hypomethylating agents
    - subject: addition of venetoclax (with decitabine and cedazuridine)
      predicate: TREATS
      object: excess blasts
      qualifier: higher-risk myelodysplastic syndromes
      subject_extension: CHEBI:133021
      object_extension: excess blasts
    - subject: addition of venetoclax (with decitabine and cedazuridine)
      predicate: TREATS
      object: excess blasts
      qualifier: MONDO:0020311
      subject_extension: CHEBI:133021
    - subject: <transplantation>
      predicate: <TREATS>
      object: <higher-risk myelodysplastic syndromes>
      qualifier: <NA>
      subject_qualifier: <NA>
      object_qualifier: <NA>
      subject_extension: <hematopoietic stem cell>
      object_extension: <NA>
    - subject: MAXO:0000747
      predicate: TREATS
      object: HP:0012325
named_entities:
  - id: MONDO:0018874
    label: Acute myeloid leukemia (AML)
  - id: HP:0001945
    label: Fever
  - id: HP:0012378
    label: Fatigue
  - id: MONDO:0020512
    label: T cell acute lymphoblastic leukemia (T-ALL)
  - id: HP:0006727
    label: T-ALL
  - id: CHEBI:50131
    label: Decitabine
  - id: CHEBI:133021
    label: Venetoclax
  - id: HP:0004808
    label: Acute myeloid leukemia
  - id: HP:0002090
    label: pneumonia
  - id: HP:0100806
    label: sepsis
  - id: CHEBI:71019
    label: Homoharringtonine
  - id: CHEBI:28680
    label: Cytarabine
  - id: HP:0000739
    label: anxiety
  - id: HP:0000716
    label: depression
  - id: CHEBI:190514
    label: dasatinib
  - id: CHEBI:23456
    label: cyclodextrins
  - id: MAXO:0000747
    label: Hematopoietic Stem Cell Transplantation (HSCT)
  - id: MAXO:0000647
    label: Chemotherapy
  - id: HP:0002018
    label: Nausea
  - id: HP:0002094
    label: Dyspnea
  - id: HP:0100785
    label: Insomnia
  - id: HP:0012531
    label: Pain
  - id: HP:0002019
    label: Constipation
  - id: CHEBI:2038
    label: Azacitidine
  - id: CHEBI:197440
    label: Tumor necrosis factor-alpha (TNF-alpha)
  - id: MONDO:0004967
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: CHEBI:8378
    label: Prednisolone
  - id: HP:0000001
    label: Acute Lymphoblastic Leukemia (ALL)
  - id: HP:0001297
    label: Stroke
  - id: HP:0001635
    label: Heart failure
  - id: HP:0001677
    label: Coronary atherosclerosis
  - id: MONDO:0004992
    label: Cancer
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  - id: MONDO:0004947
    label: B-cell acute lymphoblastic leukemia
  - id: MAXO:0000757
    label: infusion
  - id: MAXO:0000602
    label: Hemodialysis
  - id: HP:0003326
    label: Myalgia
  - id: HP:0002039
    label: Anorexia
  - id: HP:0100519
    label: Anuria
  - id: HP:0011037
    label: Decreased urine output
  - id: HP:0001919
    label: Acute kidney injury
  - id: CHEBI:18332
    label: Levothyroxine
  - id: MONDO:0020511
    label: Acute B-lymphoblastic leukemia (B-ALL)
  - id: HP:0003419
    label: lower back pain
  - id: MONDO:0010651
    label: high-risk myelodysplastic neoplasm (MDS)
  - id: CHEBI:30621
    label: arsenic trioxide
  - id: HP:0002360
    label: sleep disturbances
  - id: MONDO:0017361
    label: Cytokine release syndrome (CRS)
  - id: CHEBI:64360
    label: Tocilizumab
  - id: MONDO:0012883
    label: Acute promyelocytic leukemia (APL)
  - id: MAXO:0000149
    label: Allogeneic hematopoietic cell transplantation (HCT)
  - id: MONDO:0004948
    label: chronic lymphocytic leukemia
  - id: HP:0002014
    label: diarrhea
  - id: CHEBI:63791
    label: lenalidomide
  - id: HP:0005550
    label: chronic lymphocytic leukemia
  - id: MONDO:0003864
    label: Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)
  - id: MAXO:0001298
    label: therapies
  - id: CHEBI:42068
    label: Idarubicin
  - id: HP:0032169
    label: severe infections
  - id: CHEBI:55379
    label: cyclosporine (CsA)
  - id: CHEBI:85010
    label: eltrombopag
  - id: CHEBI:85012
    label: thrombopoietin receptor agonist (TPO-RA)
  - id: MAXO:0001394
    label: oral administration
  - id: MAXO:0001525
    label: intravenous administration
  - id: HP:0002315
    label: Headache
  - id: CHEBI:50858
    label: Corticosteroids
  - id: HP:0100614
    label: myositis
  - id: CHEBI:26708
    label: NA
  - id: CHEBI:76612
    label: Ibrutinib
  - id: CHEBI:167707
    label: Acalabrutinib
  - id: CHEBI:145428
    label: glasdegib
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0010030
    label: bone marrow transplantation
  - id: HP:0001903
    label: anemia
  - id: HP:0001875
    label: neutropenia
  - id: HP:0001698
    label: pericardial effusion
  - id: CHEBI:35705
    label: immunosuppressants
  - id: MONDO:0019460
    label: Acute leukemia of ambiguous lineage (ALAL)
  - id: HP:0001873
    label: Thrombocytopenia
  - id: CHEBI:62434
    label: FLT3 inhibitor
  - id: CHEBI:38637
    label: Tyrosine kinase inhibitor
  - id: CHEBI:28748
    label: Doxorubicin (Dox)
  - id: HP:0020174
    label: drug resistance
  - id: CHEBI:23888
    label: drugs
  - id: MONDO:0018689
    label: Plasma cell leukemia
  - id: HP:0031047
    label: monoclonal gammopathy
  - id: CHEBI:52726
    label: proteasome inhibitor
  - id: CHEBI:35341
    label: steroids
  - id: CHEBI:48120
    label: anthracyclines
  - id: MONDO:0001881
    label: Septic shock
  - id: MAXO:0001021
    label: Antimicrobial treatment
  - id: MAXO:0000174
    label: Antifungal treatment
  - id: HP:0001876
    label: Pancytopenia
  - id: CHEBI:133748
    label: Citrate
  - id: CHEBI:41879
    label: Dexamethasone
  - id: HP:0001909
    label: leukemia
  - id: CHEBI:33281
    label: Antimicrobial
  - id: CHEBI:35718
    label: Antifungal
  - id: MONDO:0011996
    label: Chronic Myeloid Leukemia
  - id: CHEBI:46345
    label: 5-fluorouracil
  - id: HP:0005506
    label: chronic myeloid leukemia
  - id: MONDO:0005059
    label: Leukemia
  - id: CHEBI:41977
    label: Daunorubicin
  - id: CHEBI:50729
    label: Mitoxantrone
  - id: CHEBI:50924
    label: Sorafenib
  - id: CHEBI:145372
    label: Gilteritinib
  - id: CHEBI:90217
    label: Quizartinib
  - id: CHEBI:145410
    label: IDH inhibitors
  - id: CHEBI:233585
    label: BAM15
  - id: CHEBI:197439
    label: TNFalpha
  - id: CHEBI:45716
    label: SAHA (Vorinostat)
  - id: HP:0002202
    label: Pleural effusion
  - id: HP:0030357
    label: small cell lung cancer
  - id: HP:0012570
    label: synovial sarcoma
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: MAXO:0000753
    label: Bone marrow examination
  - id: MONDO:0600008
    label: Cytokine release syndrome
  - id: MONDO:0020311
    label: chronic myelomonocytic leukemia
  - id: HP:0012325
    label: chronic myelomonocytic leukemia
